Cargando…
SUN-319 Failure Of Pasireotide To Control Hypoglycemia In A Men-1 Patient With Metastatic Insulinoma
Background: Pasireotide appears to be a promising therapeutic approach to refractory hyperinsulinemic hypoglycemia, since hyperglycemia is a frequent side effect when used in the treatment of other neuroendocrine diseases. Clinical case: A 39-year-old woman with MEN1 and severe hypoglycemic episodes...
Autores principales: | de Almeida, Tobias, Bertoluci, Marcello, Barkan, Sabrina, Marobin, Roberta, Czepielewski, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553365/ http://dx.doi.org/10.1210/js.2019-SUN-319 |
Ejemplares similares
-
Metastatic Insulinoma Presenting With Post-Prandial Hypoglycemia
por: Maher, Monique, et al.
Publicado: (2021) -
SUN-932 Successful Response of Temozolomide (TMZ) in two Patients with Metastatic Pheochromocytoma/Paragangliomas (PPGLs)
por: de Almeida, Tobias Skrebsky, et al.
Publicado: (2020) -
SUN-313 Insulinoma: Secreting but Not Appearing
por: Patel, Sapna, et al.
Publicado: (2019) -
Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
por: Oziel-Taieb, Sandrine, et al.
Publicado: (2022) -
SUN-314 Gallium-68 DOTATATE PET/CT for Preoperative Localization of Metastatic Insulinoma
por: Bratman, Russell, et al.
Publicado: (2019)